C. Woodley

发表

How We Treat Myeloproliferative Neoplasms.

C. Harrison, D. Mclornan, Y. Francis, 2015, Clinical lymphoma, myeloma & leukemia.

Evidence of robust memory T‐cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)

K. Rezvani, C. Harrison, D. Mclornan, 2021, British journal of haematology.

Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral Center

C. Harrison, D. Mclornan, J. O'Sullivan, 2021, HemaSphere.

Effects of co‐existing α‐thalassaemia in sickle cell disease on hydroxycarbamide therapy and circulating nucleic acids

S. Thein, J. Howard, C. Woodley, 2012, British journal of haematology.

Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib

C. Harrison, B. Wilkins, C. Woodley, 2013, Haematologica.

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia

M. Malim, D. Mclornan, C. Graham, 2021, British journal of haematology.

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms

M. Malim, C. Harrison, D. Mclornan, 2021, Leukemia.

Single dose of BNT162b2 mRNA vaccine against SARS-CoV2 induces neutralizing antibody and polyfunctional T-cell responses in patients with CML

M. Malim, D. Mclornan, C. Graham, 2021, medRxiv.

Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype

D. Mclornan, H. de Lavallade, K. Raj, 2022, British journal of haematology.

Clinicopathological characterisation of myeloproliferative neoplasm‐unclassifiable (MPN‐U): a retrospective analysis from a large UK tertiary referral centre

C. Harrison, D. Mclornan, J. O'Sullivan, 2021, British journal of haematology.

Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature.

M. Simpson, G. Mufti, K. Mills, 2021, Blood advances.

Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021

C. Harrison, D. Mclornan, J. O'Sullivan, 2021, HemaSphere.

Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms

C. Harrison, D. Mclornan, R. Dillon, 2020, British journal of haematology.

Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib

M. Malim, D. Mclornan, K. Doores, 2022, Blood Cancer Journal.

Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders

M. Malim, C. Harrison, D. Mclornan, 2022, Blood Advances.

Essential thrombocythaemia treated with recombinant interferon: ‘real world' United Kingdom referral centre experience

C. Harrison, D. Mclornan, J. Desterro, 2019, British journal of haematology.

Advanced Systemic Mastocytosis with associated haematological neoplasm: Treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant.

R. Dillon, M. Ciesielska, P. Sriskandarajah, 2023, Current research in translational medicine.

Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline

A. Mead, A. Godfrey, M. McMullin, 2023, British journal of haematology.